# Phase I Study to Examine the Effect of Deferasirox on Renal Hemodynamics in β-thalassemia Patients With Transfusional Iron Overload

> **NCT00560820** · PHASE1 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 11 (actual)

## Conditions studied

- β-thalassemia
- Transfusional Iron Overload

## Interventions

- **DRUG:** Deferasirox

## Key facts

- **NCT ID:** NCT00560820
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-09
- **Primary completion:** 2012-04
- **Final completion:** 2012-04
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2020-12-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00560820

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00560820, "Phase I Study to Examine the Effect of Deferasirox on Renal Hemodynamics in β-thalassemia Patients With Transfusional Iron Overload". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00560820. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*